Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14276378 | 1.00 | MAPK1 (0.35) | MAPK1APLNRBTKDGAT1MEN1 | |
| SCHEMBL10329704 | 1.00 | MAPK1 (0.35) | MAPK1APLNRBTKDGAT1MEN1 | |
| SCHEMBL29031931 | 0.83 | MAPK1 (0.35) | MAPK1DGAT1MEN1KMT2A | |
| SCHEMBL7644596 | 0.78 | MAPK1 (0.41) | MAPK1DGAT1MEN1KMT2A | |
| SCHEMBL6662594 | 0.78 | APLNR (0.32) | APLNR | |
| SCHEMBL3385056 | 0.76 | APLNR (0.41) | MAPK1APLNRMEN1KMT2A | |
| SCHEMBL11260869 | 0.76 | APLNR (0.41) | MAPK1APLNRMEN1KMT2A | |
| SCHEMBL5246594 | 0.76 | APLNR (0.41) | MAPK1APLNRMEN1KMT2A | |
| SCHEMBL1073149 | 0.76 | MAPK1 (0.31) | MAPK1 | |
| SCHEMBL11034136 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222240-B2 | Use of substituted cyclopropane acid derivatives for producing drugs for use in the treatment of metabolic syndrome | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-07-17 | — | — | US | disclosed |
| EP-1827415-B1 | CYCLOPROPANE ACID DERIVATIVES FOR THE REDUCTION OF LIPID LEVELS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-01-20 | — | — | EP | disclosed |
| US-20090088474-A1 | USE OF SUBSTITUTED CYCLOPROPANE ACID DERIVATIVES FOR PRODUCING DRUGS FOR USE IN THE TREATMENT OF METABOLIC SYNDROME | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-04-02 | — | — | US | disclosed |
| US-20080045590-A1 | USE OF SUBSTITUTED CYCLOPROPANE ACID DERIVATIVES FOR PRODUCING DRUGS FOR USE IN THE TREATMENT OF METABOLIC SYNDROME | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| EP-1188735-B1 | Process for producing carbonyl or hydroxy compound | SUMITOMO CHEMICAL CO (JP) | 2005-07-27 | — | — | EP | disclosed |
| US-20040152592-A1 | Process for producing carbonyl or hydroxy compound | SUMITOMO CHEMICAL COMPANY, LIMTED | 2004-08-05 | — | — | US | disclosed |
| US-6703528-B2 | CATALYTIC OXIDATION OF OLEFIN | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-03-09 | — | — | US | disclosed |
| EP-1188735-A1 | Process for producing carbonyl or hydroxy compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-03-20 | — | — | EP | disclosed |
| US-20020025906-A1 | Process for producing carbonyl or hydroxy compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045590-A1 | USE OF SUBSTITUTED CYCLOPROPANE ACID DERIVATIVES FOR PRODUCING DRUGS FOR USE IN THE TREATMENT OF METABOLIC SYNDROME | CYP27A1, CYP11B2, CYP11B1 | MAPK1 1619/4885APLNR 2205/4885BTK 4619/4885 |
| US-20090088474-A1 | USE OF SUBSTITUTED CYCLOPROPANE ACID DERIVATIVES FOR PRODUCING DRUGS FOR USE IN THE TREATMENT OF METABOLIC SYNDROME | FFAR1, FFAR2, FFAR3 | MAPK1 2655/4885APLNR 728/4885BTK 4204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.